Non-small-cell lung cancer (NSCLC)—the leading cause of cancer-related deaths in China—has a highly dynamic drug development pipeline, with multiple targeted and biomarker-driven therapies. Notably, many targeted therapies are intended for patients with activating EGFR mutations, which are more prevalent in China than in the Western markets. We expect the China NSCLC therapy market to experience robust growth throughout the 2019-2029 forecast period. The key driver of this market growth will be the continued uptake of targeted therapies, including immune checkpoint inhibitors, EGFR inhibitors, following the incorporation of several therapies into China’s National Reimbursement Drug List, thereby securing access to patients. Moreover, newer targeted therapies are expected to be approved within the forecast period, which will result in increased therapy options and market growth.
- How large is China’s drug-treatable NSCLC population, and how will drug-treatment rates change during the forecast period?
- Which are the most commercially relevant drugs in China’s NSCLC market and why? What are interviewed experts’ insights into current treatment options?
- What are the key market access considerations for therapies in the NSCLC pipeline in China? What sales/uptake could they secure in NSCLC? What are interviewed experts’ opinions of key emerging therapies?
- What are the key drivers and constraints in the China NSCLC therapy market, and how will the market evolve over the forecast period?
China In-Depth offers comprehensive market intelligence, including world-class epidemiology, keen insight into the China-specific A&R environment, current treatment paradigms, in-depth pipeline assessments, and drug forecasts supported by detailed primary and secondary research. This solution helps companies gauge commercial outlooks and optimize clinical development, subpopulation targeting, physician messaging, and overall long-term strategy in China.
Country-specific qualitative and quantitative insights driven by 5 thought-leader interviews and 75 surveys with hematologist-oncologists. Supported by survey data collected for this and other DRG research.
Diagnosed incidence of NSCLC by ALK and EGFR biomarkers status and by disease stage. Clinically and market relevant drug-treatable populations.
10-year, annualized, drug-level sales and patient shares of key NSCLC regimens through 2029, based on primary and secondary market research to formulate bottom-up assumptions
Phase III/PR: > 10 drugs. Phase II: 5 drugs. Coverage of select early-phase products.